Effect of Tetrahydrouridine on the Clinical Pharmacology of 1-β-D-Arabinofuranosylcytosine When Both Drugs Are Coinfused over Three Hours

Cancer Research

Volumn 48, Issue 5, 1988, Pages 1337-1342

  Kreis, Willi ^a   Chan, Keith ^b   Budman, Daniel R ^a   Schulman, Phillip ^a   Allen, Steven ^a   Weiselbers, Lora ^a   Lichtman, Stuart ^a   Henderson, Vicki ^a   Freeman, Jean ^a   Deere, Margaret ^a   Andreeff, Michael ^c   Vinciguerra, Vincent ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; TETRAHYDROURIDINE;

CANCER PATIENT; CLINICAL ARTICLE; DRUG THERAPY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CYTARABINE; DEAMINATION; FEMALE; HALF-LIFE; HUMAN; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TETRAHYDROURIDINE; URIDINE;

EID: 0023857397     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Rudnick, S. A., Cadman, E. C., Capizzi, R. L., Skeel, R. T., Bertino, J., and McIntosh, S. High dose cytosine arabinoside in refractory acute leukemia. Cancer (Phila.), 44: 1189-1193, 1979.
2. Southwest Oncology Group. Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response. Arch. Intern. Med., 133: 251-259, 1974.
3. Hanze, A. R. Nucleic Acids. IV. The catalytic reduction of pyrimidine nucleosides (human liver deaminase inhibitors). J. Am. Chem. Soc., 89: 6720-6725, 1967.
4. Mulligan, L. T., and Mellet, L. B. Inhibition of arabinosylcytosine deamination by tetrahydrouridine in the monkey. Pharmacologist, 12: 221, 1970.
5. Wong, P. P., Currie, V. E., Mackey, R. W., Krakoff, I. H., Tau, C. T. C., Burchenal, J. H., and Young, C. W. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. Cancer Treat. Rep., 63: 1245-1249, 1979.
6. Kreis, W., Woodcock, T. M., Gordon, C. S., and Krakoff, I. H. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosineama binoside. Cancer Treat. Rep., 61: 1347-1353, 1977.
7. Kreis, W., Chan, K., Budman, D. R., Schulman, P., Allen, S., Weiselberg, L., Henderson, V., Freeman, J., Deere, M., and Vinciguerra, V. Effect of tetrahydrouridine (THU) on ara-C pharma cokinetics and toxicity when both drugs are given by continuous infusion over 3 hrs. Proc. Am. Assoc. Cancer Res., 27: 165, 1986.
8. Piall, E. M., Aherne, G. W., and Marks, V. M. A radioimmunoassay for cytosine arabinoside. Br. J. Cancer, 40: 548-556, 1979.
9. Gibaldi, M., and Pemer, D. Pharmacokinetics, Ed. 2. New York: Marcel Dekker, Inc., 1982.
10. Kreis, W., Chaudhri, F., Chan, K., Allen, S., Budman, D. R., Schulman, P., Weiselberg, L., Freeman, J., Deere, M., and Vinciguerra, V. Pharmacokinetics of low dose l-β-D-arabinofuranosylcytosine given by continuous intravenous infusion over 21 days. Cancer Res., 45: 6498-6501, 1985.
11. Chan, K. K., and Gibaldi, M. Estimation of statistical moments and steady state volume of distribution for a drug given by intravenous infusion. J. Pharm. Pharmaceut., 10: 551-558, 1982.
12. Holford, N. H. S., and Sheiner, L. B. Understanding the dose effect relationship: Clinical applications of pharma cokinetic-pharmacodynamic models. Clin. Pharmacokinet., 6: 429-453, 1981.
13. Metzler, C. M., and Weiner, D. L. PC NONLIN and NONLIN 84: Software for the statistical analysis of nonlinear models. Am. Statistician, 40: 52, 1986.
14. Early, A., Preisler, H., Slocum, H., and Rustum, Y. A pilot study of high dose ara-C for acute leukemia and refractory lymphoma. Cancer Res., 42: 1587-1594, 1982.
15. Lazarus, H., Herzig, G., Herzig, R. et al. Central nervous system toxicity of high dose ara-C. Cancer (Phila.), 48: 2577-2582, 1981.
16. Nand, S., Messmore, H. L., Jr., Patel, R., Fisher, S., and Fisher, R. I. Neurotoxicity associated with systemic high dose cytosine arabinoside. J. Clin. Oncol., 4: 571-575, 1986.
17. Ochs, J., Sinkule, J. A., Danks, M. K., Look, A. T., Bowman, W. P., and Rivera, G. Continuous infusion high dose ara-C in refractory childhood leukemia. J. Clin. Oncol., 2: 1092-1097, 1984.
18. Chou, T. C., Arlin, Z., Clarkson, B. D., and Philips, F. S. Metabolism of 1-β-D-arabinofuranosylcytosine in human leukemic cells. Cancer Res., 37: 3561-3570, 1977.
19. Harris, A. L., and Grahame-Smith, D. G. Variation in sensitivity of DNA synthesis to ara-C in acute myeloid leukemia. Br. J. Haematol., 45: 371-379, 1980.
20. Riva, C. M., and Rustum, Y. M. 1-β-D-arabinofuranosyl cytosine metabolism and incorporation into DNA as determinants of in vivomurine tumor cell response. Cancer Res., 45: 6244-6249, 1985.
21. Rustum, Y. M., Slocum, H., Wang, G., Bakshi, D., Kelly, E., Buscaglia, D., Wrzosek, C., Early, A. P., and Preisler, H. Relationship between plasma ara C and intracellular ara-CTP pools under conditions of continuous infusion in high dose ara-C treatment. Med. Pediatr. Oncol. Suppl., 1: 33-43, 1982.
22. Plunkett, W., Liliemark, J. O., Adams, T. M., Novak, B., Estey, E., Kantarjian, H., and Keating, M. J. Saturation of 1-β-D-arabinofuranosyl cytosine 5'-triphosphate accumulation in leukemia cells during high dose l-β-D-arabinofuranosyl cytosine therapy. Cancer Res., 47: 3005-3011, 1987.
23. Slevin, M. L., Piall, E. M., Aherne, G. W., Harvey, V. J., Johnston, A., and Lister, T. A. Effect of dose and schedule on phannacokinetics of high dose cytosine arabinoside in plasma and cerebrospinal fluid. J. Clin. Oncol., 1: 546-551, 1983.
24. Van Prooijen, H. C., Dekker, A. W., and Punt, K. The use of intermediate dose cytosine arabinoside (ID ara-C) in the treatment of acute non-lymphocytic leukemia in relapse. Br. J. Haematol., 57: 291-299, 1984.
25. Spriggs, D. R., Robbins, G., Takvorian, T., and Kufe, D. W. Continuous infusion of high dose 1-β-D-arabinofuranosyl cytosine: A phase I and pharmacological study. Cancer Res., 45: 3932-3936, 1985.
26. Capizzi, R. L., Yang, J. L., Cheng, E., Bjorusson, T., Saharabudhe, D., Tan, R. S., and Cheng, Y. C. Alteration of the pharmacokinetics of high dose ara C by its metabolite, high ara-U in patients with acute leukemia. J. Clin. Oncol., 1: 763-771, 1983.
27. Ho, D. H. W., and Frei, E. Clinical pharmacology of 1-β-D-arabinofuranosyl cytosine. Clin. Pharmacol. Ther., 12: 944-954, 1971.
28. Muller, E. G., and Zahn, R. D. Metabolism of 1-β-D-arabinofuranosyluracil in mouse L5178 Y cells. Cancer Res., 39: 1102-1107, 1979.
29. Yang, J. L., Cheng, E. H., Capizzi, R. L., Cheng, Y. C., and Kute, T. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia J. Clin. Invest., 75: 141-146, 1985.
30. Breithaupt, H., Pralle, H., Eckhardt, T., Von Hattingberg, M., Schick, J., and Loffler, H. Clinical results and pharmacokinetics of high dose cytosine arabinoside (HD ara-C). Cancer (Phila), 50: 1248-1257, 1982.
31. Kessel, D., and Shurin, S. Transport of two non-metabolized nucleosides, deoxycytidine and cytosine arabinoside, in a subline of the L1210 murine leukemia. Biochem. Biophys. Acta, 163: 179-187, 1968.
32. Lopez, J. A., and Agarwal, R. P. Acute cerebellar toxicity after high dose cytarabine associated with CNS accumulation of its metabolite, uracil arabinoside. Cancer Treat. Rep., 68: 1309-1310, 1984.
33. Riccardi, R., Chabner, B., Glaubiger, D. L., Wood, J., and Poplack, D. G. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-β-D-arabinofuranosyl cytosine. Cancer Res., 42: 1736-1739, 1982.
34. Kreis, W., Hession, C., Soricelli, A., and Scully, K. Combination of tetrahydrouridine and cytosine arabinoside in mouse tumors. Cancer Treat. Rep., 61: 1355-1364, 1977.
35. Wentworth, D. F., and Wolfenden, R. On the interaction of 3, 4, 5, 6-tetrahydrouridine with human liver cytidine deaminase. Biochemistry, 14: 5099-5105, 1975.
36. Camiener, G. W. Studies of the enzymatic deamination of ara-cytidine. V. Inhibition in vitro and in vivo by tetrahydrouridine and other reduced pyrimidine nucleosides. Biochem. Pharmacol., 17: 1981-1991, 1968.
37. Ho, D. H. W., Carter, C. J., Brown, N. S., Hester, J., McCredie, K., Benjamin, R. S., Freireich, E. J., and Bodey, G. P. Effects of tetrahydrouridine on the uptake and metabolism of 1-β-D-arabin of uranosylcytosine in human normal and leukemic cells. Cancer Res., 40: 2441-2446, 1980.